索拉非尼导致高血压的快速发展：是毒性还是靶点作用？
Rapid development of hypertension by sorafenib: toxicity or target?
作者信息
Humphreys Benjamin D, Atkins Michael B
机构信息
Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
出版信息
Clin Cancer Res. 2009 Oct 1;15(19):5947-9. doi: 10.1158/1078-0432.CCR-09-1717. Epub 2009 Sep 29.
Abstract
Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.
摘要
血压升高可能是血管内皮生长因子信号通路（VSP）抑制的药效学标志物，有助于优化VSP抑制剂的安全有效剂量。治疗第一天血压就会升高，这有利于未来旨在将血压变化与临床结果相关联的试验的设计与解读。
相似文献
1
Rapid development of hypertension by sorafenib: toxicity or target?索拉非尼导致高血压的快速发展：是毒性还是靶点作用？
Clin Cancer Res. 2009 Oct 1;15(19):5947-9. doi: 10.1158/1078-0432.CCR-09-1717. Epub 2009 Sep 29.
2
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.动态监测在治疗第一天就能检测到索拉非尼引起的血压升高。
Clin Cancer Res. 2009 Oct 1;15(19):6250-7. doi: 10.1158/1078-0432.CCR-09-0058. Epub 2009 Sep 22.
3
[Oral drugs inhibiting the VEGF pathway].[抑制VEGF通路的口服药物]
Bull Cancer. 2007 Jul;94 Spec No:S180-90.
4
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.对于接受口服激酶抑制剂治疗晚期肾细胞癌的患者，需要频繁中断剂量。
Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.
5
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.心血管毒性：血管内皮生长因子信号通路抑制剂最佳给药的线索
Target Oncol. 2009 Apr;4(2):67-76. doi: 10.1007/s11523-009-0106-0. Epub 2009 Apr 17.
6
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.动脉高血压以及舒尼替尼、索拉非尼和贝伐单抗在转移性肾细胞癌一线及二线治疗中的临床获益
Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201.
7
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.血管内皮生长因子抑制与转移：抗血管生成治疗的潜在影响
Cancer Biol Ther. 2009 Jul;8(13):1214-25. doi: 10.4161/cbt.8.13.8918. Epub 2009 Jul 4.
8
Quantifying hypertension in patients with cancer treated with sorafenib.索拉非尼治疗的癌症患者高血压的量化
Lancet Oncol. 2008 Feb;9(2):86-7. doi: 10.1016/S1470-2045(08)70009-3.
9
Adverse effects of anticancer agents that target the VEGF pathway.靶向VEGF通路的抗癌药物的不良反应。
Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. doi: 10.1038/nrclinonc.2009.94. Epub 2009 Jul 7.
10
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.舒尼替尼和索拉非尼抗血管生成治疗期间出血性直肠结肠炎急性加重
Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22.
引用本文的文献
1
Cardiology and oncology: a meeting of giants.心脏病学与肿瘤学：巨头的交汇
Rev Assoc Med Bras (1992). 2024 Jun 7;70(suppl 1):e2024S114. doi: 10.1590/1806-9282.2024S114. eCollection 2024.
2
Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications.了解索拉非尼引起的心血管毒性：机制和治疗意义。
Drug Des Devel Ther. 2024 Mar 18;18:829-843. doi: 10.2147/DDDT.S443107. eCollection 2024.
3
Hypertension in Cancer Survivors.癌症幸存者中的高血压
Curr Hypertens Rep. 2022 Oct;24(10):435-443. doi: 10.1007/s11906-022-01208-2. Epub 2022 Jul 19.
4
Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.使用PTUPB进行双环氧水解酶/环氧合酶-2抑制：抗血管生成诱导的肾毒性的一种有前景的方法。
Front Pharmacol. 2021 Dec 9;12:744776. doi: 10.3389/fphar.2021.744776. eCollection 2021.
5
Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis.阿特珠单抗和贝伐单抗治疗的癌症患者高血压的发病率和风险：一项系统评价和荟萃分析
Front Oncol. 2021 Oct 12;11:726008. doi: 10.3389/fonc.2021.726008. eCollection 2021.
6
Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors.高血压与抗血管生成：VEGF抑制剂的双面性
JACC CardioOncol. 2019 Sep 24;1(1):37-40. doi: 10.1016/j.jaccao.2019.08.010. eCollection 2019 Sep.
7
Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.利用真实世界的上市后监测数据进行仑伐替尼引起的高血压的药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):188-198. doi: 10.1002/psp4.12587. Epub 2021 Feb 14.
8
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.索拉非尼治疗晚期肝细胞癌中糖尿病和高血压的预后作用。
PLoS One. 2020 Dec 31;15(12):e0244293. doi: 10.1371/journal.pone.0244293. eCollection 2020.
9
Hypertension management in cardio-oncology.心血管肿瘤学中的高血压管理。
J Hum Hypertens. 2020 Oct;34(10):673-681. doi: 10.1038/s41371-020-0391-8. Epub 2020 Aug 3.
10
The hypertensive effect of sorafenib is abolished by sildenafil.索拉非尼的高血压作用被西地那非消除。
Cardiooncology. 2020 Jul 13;6:7. doi: 10.1186/s40959-020-00064-w. eCollection 2020.
本文引用的文献
1
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.动态监测在治疗第一天就能检测到索拉非尼引起的血压升高。
Clin Cancer Res. 2009 Oct 1;15(19):6250-7. doi: 10.1158/1078-0432.CCR-09-0058. Epub 2009 Sep 22.
2
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?在小鼠模型中，动脉自旋标记磁共振成像测量的肿瘤灌注与肾细胞癌对抗血管生成治疗的反应相关吗？
Radiology. 2009 Jun;251(3):731-42. doi: 10.1148/radiol.2521081059.
3
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.多靶点受体酪氨酸激酶抑制剂ABT-869 [N-(4-(3-氨基-1H-吲唑-4-基)phenyl)-N'-(2-氟-5-甲基phenyl)脲]对清醒大鼠和小鼠血压的影响：用抗高血压药物逆转及对肿瘤生长抑制的作用
J Pharmacol Exp Ther. 2009 Jun;329(3):928-37. doi: 10.1124/jpet.108.144816. Epub 2009 Mar 2.
4
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.在一项晚期乳腺癌中紫杉醇与紫杉醇加贝伐单抗对比试验中，血管内皮生长因子及血管内皮生长因子受体-2基因多态性与预后的关系：东部肿瘤协作组2100研究
J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612.
5
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.接受多激酶抑制剂索拉非尼和舒尼替尼治疗的癌症患者的手足皮肤反应。
Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.
6
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.小分子血管生成抑制剂替拉替尼治疗期间的高血压和血管稀疏
Clin Cancer Res. 2008 Jun 1;14(11):3470-6. doi: 10.1158/1078-0432.CCR-07-5050.
7
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.一种由多靶点激酶抑制剂舒尼替尼和索拉非尼诱导的，以可逆性高血压和蛋白尿为特征的子痫前期样综合征。
J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12.
8
Autocrine VEGF signaling is required for vascular homeostasis.自分泌血管内皮生长因子（VEGF）信号传导是血管稳态所必需的。
Cell. 2007 Aug 24;130(4):691-703. doi: 10.1016/j.cell.2007.06.054.
9
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.内皮型一氧化氮合酶在血管内皮生长因子诱导的血管生成和血管通透性中起主要作用。
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9. doi: 10.1073/pnas.041359198.
10
Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.血管内皮生长因子/血管通透因子可产生一氧化氮依赖性低血压。其在静止的成年内皮细胞中具有维持作用的证据。
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2793-800. doi: 10.1161/01.atv.17.11.2793.
Zotero 插件